Eurand, Inc. v. Anchen Pharmaceuticals, Inc.

U.S. Court of Appeals for the Federal Circuit August 31, 2011

Eurand, Inc. v. Anchen Pharmaceuticals, Inc., 427 F. App'x 901 (Fed. Cir. 2011)

Opinion of the Court

ON MOTION

Upon consideration of the appellants’ motion to withdraw these appeals, and the motion to revise the official caption,

It Is Ordered That:

(1) The motion to withdraw the appeals is granted. The appeals are dismissed.

(2) The motion to revise the caption is granted. The revised official caption is reflected above.

(3) Each side shall bear its own costs.

(4) Any other pending motions are denied as moot.

Full Case Name: In re CYCLOBENZAPRINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PATENT LITIGATION. Eurand, Inc. (now known as Aptalis Pharmatech, Inc.) and Anesta AG v. Anchen Pharmaceuticals, Inc. and Anchen, Inc., DefendantsAppellees
Status: Published